Exogenous Glucagon-Like Peptide-1 for Hyperglycemia in Critically Ill Patients

Abstract

Spanish

French

OBJECTIVE:

To review literature evaluating the safety and efficacy of exogenous glucagon-like peptide-1 (GLP-1) for hyperglycemia in critically ill patients.

DATA SOURCES:

PubMed was queried (inception to September 3, 2011), using the search term glucagon-like peptide-1. The search was limited to studies published in English and conducted in humans. Regular and late-breaking abstracts from the American Diabetes Association Scientific Sessions in 2009 and 2010 were also searched using the same search term.

STUDY SELECTION AND DATA EXTRACTION:

All abstracts were screened for eligibility, which consisted of studies reporting the effects of intravenous GLP-1 administration on glycemic control in critically ill patients. Data extracted from eligible trials included study and population characteristics, measures of glycemic efficacy, and safety.

DATA SYNTHESIS:

Our search resulted in the identification of 2105 potentially relevant articles; of those, 7 were reviewed. All included publications evaluated the use of intravenous GLP-1 (1.2-3.6 pmol/kg/min) compared with insulin or placebo infused for 4.5-72 hours in critically ill patients. The majority (n = 4) of studies included only patients from a surgical intensive care setting, and 71% (n = 5) of trials included those with a history of diabetes. Relative to insulin or placebo, GLP-1 therapy effectively lowered blood glucose concentrations in all trials. Out of 81 total study participants receiving GLP-1, only 4 had documented hypoglycemia (<60 mg/dL), 4 reported nausea, and 2 experienced vomiting. No other serious adverse events were reported.

CONCLUSIONS:

All trials reviewed suggest that GLP-1 may be a promising agent for the management of hyperglycemia in critically ill patients, regardless of diabetes status. Additional studies in more heterogeneous intensive care settings comparing GLP-1 with insulin, the current standard of care, are necessary. These studies should evaluate long-term safety and effectiveness of GLP-1 therapy on morbidity and mortality outcomes in critically ill populations.

Keywords

blood glucose critical care glucagon-like peptide-1 hyperglycemia

Get full access to this article

View all access options for this article.

References

1 McCowen

Malhotra

Bistrian

. Stress-induced hyperglycemia. Crit Care Clin 2001;17:107–24.

van den Berghe

Wouters

Weekers

Intensive insulin therapy in the critically ill patients. N Engl J Med 2001;345:1359–67.

Griesdale

de Souza

van Dam

Intensive insulin therapy and mortality among critically ill patients: a meta-analysis including NICE-SUGAR study data. CMAJ 2009;180:821–7.

van den Berghe

Wilmer

Hermans

Intensive insulin therapy in the medical ICU. N Engl J Med 2006;354:449–61.

Brunkhorst

Engel

Bloos

Intensive insulin therapy and pentastarch resuscitation in severe sepsis. N Engl J Med 2008;358:125–39.

6 Egi

Bellomo

Stachowski

French

Hart

. Variability of blood glucose concentration and short-term mortality in critically ill patients. Anesthesiology 2006;105:244–52.

7 Dossett

Cao

Mowery

Dortch

Morris

Jr May

. Blood glucose variability is associated with mortality in the surgical intensive care unit. Am Surg 2008;74:679–85; discussion 685.

8 Holst

Vilsboll

Deacon

. The incretin system and its role in type 2 diabetes mellitus. Mol Cell Endocrinol 2009;297:127–36.

Degn

Brock

Juhl

Effect of intravenous infusion of exenatide (synthetic exendin-4) on glucose-dependent insulin secretion and counterregulation during hypoglycemia. Diabetes 2004;53:2397–403.

10.

10 Deacon

Nauck

Toft-Nielsen

Pridal

Willms

Holst

. Both subcutaneously and intravenously administered glucagon-like peptide I are rapidly degraded from the NH2-terminus in type II diabetic patients and in healthy subjects. Diabetes 1995;44:1126–31.

11.

11 Nauck

Sauerwald

Ritzel

Holst

Schmiegel

. Influence of glucagon-like peptide 1 on fasting glycemia in type 2 diabetic patients treated with insulin after sulfonylurea secondary failure. Diabetes Care 1998;21:1925–31.

12.

12 Zander

Taskiran

Toft-Nielsen

Madsbad

Holst

. Additive glucose-lowering effects of glucagon-like peptide-1 and metformin in type 2 diabetes. Diabetes Care 2001;24:720–5.

13.

Nauck

Walberg

Vethacke

Blood glucose control in healthy subject and patients receiving intravenous glucose infusion or total parenteral nutrition using glucagon-like peptide 1. Regul Pept 2004;118:89–97.

14.

Meier

Weyhe

Michaely

Intravenous glucagon-like peptide 1 normalizes blood glucose after major surgery in patients with type 2 diabetes. Crit Care Med 2004;32:848–51.

15.

Sokos

Bolukoglu

German

Effect of glucagon-like peptide-1 (GLP-1) on glycemic control and left ventricular function in patients undergoing coronary artery bypass grafting. Am J Cardiol 2007;100:824–9.

16.

Müssig

Oncü

Lindauer

Effects of intravenous glucagon-like peptide-1 on glucose control and hemodynamics after coronary artery bypass surgery in patients with type 2 diabetes. Am J Cardiol 2008;102:646–7.

17.

17 Deane

Chapman

Fraser

Burgstad

Besanko

Horowitz

. The effect of exogenous glucagon-like peptide-1 on the glycaemic response to small intestinal nutrient in the critically ill: a randomised double-blind placebo-controlled cross over study. Crit Care 2009;13:R67.

18.

Deane

Summers

Zaknic

Exogenous glucagon-like peptide-1 attenuates the glycemic response to postpyloric nutrient infusion in critically ill patients with type-2 diabetes. Crit Care 2011;15:R35.

19.

Deane

Chapman

Fraser

Effects of exogenous glucagon-like peptide-1 on gastric emptying and glucose absorption in the critically ill: relationship to glycemia. Crit Care Med 2010;38:1261–9.

20.

Nikolaidis

Mankad

Sokos

Effects of glucagon like peptide-1 in patients with acute myocardial infarction and left ventricular dysfunction after successful reperfusion. Circulation 2004;109:962–5.